XLV - Vyne Therapeutics: Strong Execution And Potential Upside From Strategic Options

October, 12 2020 09:24 AM SPDR Select Sector Fund - Health Care

Vyne Therapeutics is executing well, successfully launching 2 differentiated dermatology products this year.
Amzeeq Rx trends have exhibited 20% compounded growth since the economic shutdown in April.
Newly launched rosacea treatment, Zilxi, already has high prescriber awareness and health plan coverage.
Significant dermatologist enthusiasm for both Amzeeq and Zilxi was showcased at Vyne’s recent Analyst/Investor event.
Upside potential from potential ex-us partnership and pipeline asset, FCD105.

For further details see:

Company Name:	SPDR Select Sector Fund - Health Care
Stock Symbol:	XLV
Market:	NYSE